Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation
W Krivit, ME Pierpont, K Ayaz, M Tsai, NK Ramsay, JH Kersey, S Weisdorf, R Sibley, D Snover, MM McGovern, and et al.
A 13-year-old girl with the severe form of the Maroteaux-Lamy syndrome (mucopolysaccharidosis Type VI, arylsulfatase B deficiency) has had successful reconstitution with bone marrow from her HLA-MLC-matched sister who had normal arylsulfatase B activity. Full engraftment has been present for 24 months. The following biochemical and clinical changes have occurred: arylsulfatase B activity in peripheral lymphocytes and granulocytes increased to normal levels, and the activity in serial liver-biopsy specimens increased from about 3 per cent of the mean normal level 43 days after transplantation to about 16 per cent at 600 days. Urinary excretion of acid mucopolysaccharide decreased. Ultrastructural evidence of accumulated dermatan sulfate was no longer detectable in bone-marrow cells; in peripheral-blood lymphocytes, granulocytes, or platelets; or in Ito cells of liver. Twenty-four months after engraftment, hepatosplenomegaly was substantially decreased and cardiopulmonary function was normal. Visual acuity and joint mobility were also improved. The patient returned to school and continued to perform well in academic studies. Thus, bone-marrow transplantation provided a source of enzymatically normal cells, which have altered the metabolic and clinical course of the disease.
This article has been cited by other articles:
Prasad, V. K., Mendizabal, A., Parikh, S. H., Szabolcs, P., Driscoll, T. A., Page, K., Lakshminarayanan, S., Allison, J., Wood, S., Semmel, D., Escolar, M. L., Martin, P. L., Carter, S., Kurtzberg, J.
(2008). Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood
112: 2979-2989
[Abstract][Full Text]
Giugliani, R., Harmatz, P., Wraith, J. E.
(2007). Management Guidelines for Mucopolysaccharidosis VI. Pediatrics
120: 405-418
[Abstract][Full Text]
Schuldt, A. J. T., Hampton, T. J., Chu, V., Vogler, C. A., Galvin, N., Lessard, M. D., Barker, J. E.
(2004). Electrocardiographic and other cardiac anomalies in {beta}-glucuronidase-null mice corrected by nonablative neonatal marrow transplantation. Proc. Natl. Acad. Sci. USA
101: 603-608
[Abstract][Full Text]
Sullivan, K. M., Parkman, R., Walters, M. C.
(2000). Bone Marrow Transplantation for Non-Malignant Disease. ASH Education Book
2000: 319-338
[Abstract][Full Text]
Bielicki, J., Crawley, A. C., Davey, R. C. A., Varnai, J. C., Hopwood, J. J.
(1999). Advantages of Using Same Species Enzyme for Replacement Therapy in a Feline Model of Mucopolysaccharidosis Type VI. J. Biol. Chem.
274: 36335-36343
[Abstract][Full Text]
Freeman, B. J., Roberts, M. S., Vogler, C. A., Nicholes, A., Hofling, A. A., Sands, M. S.
(1999). Behavior and Therapeutic Efficacy of beta -Glucuronidase-Positive Mononuclear Phagocytes in a Murine Model of Mucopolysaccharidosis Type VII. Blood
94: 2142-2150
[Abstract][Full Text]
Schwartz, M. L., Cox, G. F., Lin, A. E., Korson, M. S., Perez-Atayde, A., Lacro, R. V., Lipshultz, S. E.
(1996). Clinical Approach to Genetic Cardiomyopathy in Children. Circulation
94: 2021-2038
[Abstract][Full Text]
Hoogerbrugge, P., Suzuki, K, Suzuki, K, Poorthuis, B., Kobayashi, T, Wagemaker, G, van Bekkum, D.
(1988). Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation. Science
239: 1035-1038
[Abstract]
Parkman, R
(1986). The application of bone marrow transplantation to the treatment of genetic diseases. Science
232: 1373-1378
[Abstract]
Previous
